ACRS - Aclaris Therapeutics Inc
IEX Last Trade
1.18
0.010 0.847%
Share volume: 170,634
Last Updated: Fri 30 Aug 2024 09:59:43 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$1.17
0.01
0.86%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-03 | 2022-11-08 | 2023-02-23 | 2023-05-08 | 2023-08-07 | 2023-11-06 | 2024-02-27 | 2024-05-07 | |
| Assets | |||||||||
| Total Assets | 277.976 M | 267.632 M | 254.596 M | 229.705 M | 235.649 M | 218.354 M | 197.405 M | 174.065 M | |
| Current Assets | 259.354 M | 256.573 M | 231.550 M | 184.361 M | 132.935 M | 123.068 M | 128.856 M | 135.338 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 10.114 M | 7.914 M | 13.495 M | 12.872 M | 12.729 M | 19.670 M | 9.452 M | 6.799 M | |
| Short Term Investments | 10.114 M | 7.914 M | 13.495 M | 12.872 M | 12.729 M | 19.670 M | 9.452 M | 6.799 M | |
| Total Receivables | 637.000 K | 597.000 K | 484.000 K | 686.000 K | 431.000 K | 346.000 K | 298.000 K | 373.000 K | |
| Current Cash | 248.603 M | 248.062 M | 217.571 M | 170.803 M | 119.775 M | 103.052 M | 119.106 M | 128.166 M | |
| Total Non-current Assets | 18.622 M | 11.059 M | 23.046 M | 45.344 M | 102.714 M | 95.286 M | 68.549 M | 38.727 M | |
| Property Plant Equipment | 1.276 M | 1.145 M | 1.099 M | 1.513 M | 1.899 M | 1.764 M | 1.620 M | 1.531 M | |
| Other Assets | 3.114 M | 2.922 M | 2.732 M | 3.275 M | 2.888 M | 2.661 M | 3.889 M | 3.997 M | |
| Intangible Assets | 7.011 M | 6.992 M | 6.973 M | 6.954 M | 6.935 M | 6.917 M | 269.000 K | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 277.976 M | 267.632 M | 254.596 M | 229.705 M | 235.649 M | 218.354 M | 197.405 M | 174.065 M | |
| Total liabilities | 42.224 M | 47.794 M | 56.975 M | 52.895 M | 55.899 M | 62.021 M | 40.226 M | 32.051 M | |
| Total current liabilities | 16.217 M | 19.789 M | 21.938 M | 18.258 M | 22.829 M | 27.320 M | 30.952 M | 20.080 M | |
| Accounts Payable | 5.703 M | 7.667 M | 10.351 M | 8.190 M | 11.425 M | 9.648 M | 8.878 M | 10.810 M | |
| Other liabilities | 25.640 M | 27.638 M | 34.670 M | 34.270 M | 32.703 M | 34.334 M | 9.274 M | 11.971 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 25.640 M | 27.638 M | 34.670 M | 34.270 M | 32.703 M | 34.334 M | 9.274 M | 11.971 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 235.752 M | 219.838 M | 197.621 M | 176.810 M | 179.750 M | 156.333 M | 157.179 M | 142.014 M | |
| Common stock | 65.990 M | 66.675 M | 66.759 M | 66.873 M | 70.634 M | 70.808 M | 70.921 M | 71.075 M | |
| Retained earnings | -634.728 M | -654.680 M | -682.315 M | -710.475 M | -740.044 M | -769.305 M | -770.796 M | -787.737 M |